The federal government’s Operation Warp Speed has made its biggest financing award yet, promising $1.6 billion to a Maryland biotech to help advance its investigational COVID-19 vaccine and ready millions of doses in preparation for its possible success.
Gaithersburg, MD-based Novavax,... Read more »
Targeted therapies for treating cancer are designed to attack one or more proteins known to be on the surface of cancerous cells—but they don’t discriminate when they come across healthy cells expressing those same proteins.
Vor Biopharma, an oncology company launched... Read more »
Here’s a look back at some of the life science industry’s executive appointments, departures, and retirements from recent weeks:
—Pacific Biosciences (NASDAQ: PACB) CEO Michael Hunkapiller and Chief Financial Officer Susan Barnes are retiring.
—Moderna (NASDAQ: MRNA) appointed... Read more »
The same week Annexon Biosciences announced it had raised $100 million in private financing to advance its research of antibody drugs to treat neurodegeneration, the company filed paperwork with regulators indicating its intention to tap the public markets, too.
The South... Read more »
Bristol Myers Squibb likes what it sees from the immune cell research of Dragonfly Therapeutics so far—enough to pay $55 million to add multiple sclerosis and neuroinflammation to their ongoing partnership.
The alliance came to New York-based Bristol (NYSE: BMY)... Read more »
The 2020 National Xconomy Awards – celebrating the best in biotech innovation and entrepreneurship – just got bigger!
We’re excited to announce the expansion of the 2020 National Xconomy Awards. Presented in a digital format, the 2020... Read more »
MEI Pharma and its Swiss partner Helsinn are ending a Phase 3 study of an investigational cancer drug for patients with acute myeloid leukemia (AML) after an interim analysis indicated it was unlikely to meet the trial’s main goal of helping... Read more »
Fast enrollment of the right patient populations will be critical to quickly conducting Phase III trials of COVID-19 vaccines and this will likely mean taking concerted steps to reach out to populations that can be harder to recruit for clinical trials,... Read more »
The quantity of data about medicines, diseases, and biology is growing. So too, are the number of companies that employ artificial intelligence in drug discovery. Most of the low-hanging fruit in drug research has already been picked, and the industry is... Read more »
Annexon Biosciences, a biotech founded in late 2014 by former Elan Pharmaceuticals executives, has added $100 million to its coffers to move its two clinical-stage programs along and to continue advancing its preclinical pipeline.
The South San Francisco-based company is developing... Read more »
[Updated 7/2/2020, 9:27 a.m. See below.] A BioNTech messenger RNA vaccine candidate for COVID-19 has shown in a small study that it can elicit an immune response to the novel coronavirus.
The 45-patient US study tested three doses of... Read more »
[Updated, 4:54 p.m.] Amylyx Pharmaceuticals’ two-pronged approach to neurodegenerative diseases has shown promise in amyotrophic lateral sclerosis (ALS) testing and the company now has $30 million to complete a separate clinical trial in Alzheimer’s disease.
The Series B round... Read more »
Ten months ago Randy Schatzman was appointed CEO of cancer drug developer Bolt Biotherapeutics, and tasked with getting its first drug candidate into the clinic, building out its C-suite, and raising more money.
On Wednesday Schatzman checked the last box... Read more »
The blood-brain barrier protects the functioning of that essential organ, but it’s also a hurdle to delivering neurological drugs.
Italy’s Chiesi Group has agreed to pay Guilford, CT-based Bioasis Technologies $3 million up front to use the preclinical firm’s technology to... Read more »
Ultragenyx Pharmaceutical won FDA approval Tuesday for a therapy that treats a group of rare metabolic disorders that render the body unable to convert certain fats—such as those found in olive oil, fish, and nuts—into energy.
People who have long-chain fatty... Read more »
Goldfinch Bio, a biotech company employing genetic analysis to develop new medicines for kidney diseases, has raised $100 million to bring its lead drug candidate into mid-stage clinical trials.
The Series B round of financing was led by Eventide Asset Management.... Read more »
A growing population of people with software experience plus an interest in life sciences is boosting drug development in the San Francisco Bay Area, according to panelists at an Xcelerating event.
Innovation in the San Francisco Bay Area may first bring... Read more »
A new version of a combination drug marketed by Roche for early-stage and metastatic breast cancer with a specific genetic signature received FDA approval Monday for a formulation that can be delivered in minutes rather than an hour or more.
The... Read more »
Heron Therapeutics revealed Monday that its investigational non-opioid drug for treating postoperative pain has again been rejected by the FDA.
The San Diego company’s HTX-011 is an extended-release solution of bupivacaine, a local anesthetic, and meloxicam, a nonsteroidal anti-inflammatory drug. Heron... Read more »
The FDA has rejected an Intercept Pharmaceuticals drug developed to treat the fatty liver disorder nonalcoholic steatohepatitis, more commonly referred to as “NASH.”
New York-based Intercept (NASDAQ: ICPT) said Monday that the agency’s complete response letter for obeticholic acid (OCA)... Read more »
Even during the most difficult of times, the life science sector continues to push forward with innovation. The recent rapid progression of drug development, diagnostic tests, and healthcare tools has propelled us into new territory that was unthinkable – or even... Read more »
DBV Technologies still expects to receive an FDA decision in early August for its peanut allergy patch. But on Friday the company, which is headquartered in the southern outskirts of Paris, said it would start layoffs and scale down its drug... Read more »
Sponsored · Whitepaper
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson
Sponsored · Whitepaper
With data from IBM Watson Health, epidemiologists can describe treatment patterns, persistence & adherence to therapy
IBM Watson
Sponsored · Whitepaper
Explore the different sources of funding, their relative merits, and how you should best utilize that funding at each stage of your research
Brex
Sponsored · Special Report
Hyperinflation in rents is over
Hughes Marino Sponsored · Whitepaper
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson
Sponsored · Whitepaper
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
PRA Health Sciences
